Tesamorelin vs GHRP-2
Both Tesamorelin and GHRP-2 are used for growth-hormone. Here's how their evidence, dosing, and regulatory status actually compare.
Tesamorelin
Evidence ATesamorelin (Egrifta)
An FDA-approved GHRH analog that stimulates natural growth hormone production. Clinically proven to reduce visceral adipose tissue and increasingly used off-label for body recomposition.
View full Tesamorelin profile →GHRP-2
Evidence BGrowth Hormone Releasing Peptide 2
A potent synthetic ghrelin-mimetic GH secretagogue. Drives strong GH spikes but raises cortisol and prolactin more than newer alternatives like Ipamorelin.
View full GHRP-2 profile →Side-by-Side
| Attribute | Tesamorelin | GHRP-2 |
|---|---|---|
| Evidence Grade | A | B |
| FDA Status | FDA-approved for HIV-associated lipodystrophy | Not FDA-approved — research compound; previously studied as growth hormone deficiency diagnostic |
| Typical Dose | 2 mg daily (subcutaneous) | 100–300 mcg, 1–3 times daily (subcutaneous) |
| Clinics Indexed | 178 | 86 |
| Categories | growth-hormone, fat-loss | growth-hormone, anti-aging |
Key reported benefits — Tesamorelin
- ✓Visceral fat reduction
- ✓Natural GH stimulation
- ✓Cognitive benefit
- ✓Lean mass
Key reported benefits — GHRP-2
- ✓Strong GH release
- ✓Appetite stimulation
- ✓Muscle recovery
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.